CHMP opines positively for 13 Drugs for a variety of disease The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has endorsed the use of 13 medicinal dr...
FDA Approves Eli Lilly's Baqsimi, the first treatment for Severe Hypoglycemia The U.S. FDA gave its approval to Baqsimi nasal powder, for the treatment of Severe Hypoglycaemia in patients with diabetes ages four and older. Baqsimi is a powder administered into the nose and is the first non-injectable emergency t...
Find More
Generic Lyrica: FDA nods to first generic alternatives to Pfizer’s Lyrica The U.S. FDA has approved the first generic substitute of Pfizer’s Lyrica (pregabalin) in its commitment to facilitate the access of high-quality generic medicines at lower prices to patients. Lyrica is the second most selling drug of the...
Find More
Osivax raises USD 9 M to boost its universal flu vaccine approach France based biotech startup company Osivax, has secured USD 9 million in Series A financing. A Belgian-based firm Noshaq along with Anaxago, an innovative investment platform led the financing. The proceeds will be used to further advance the cl...
Find More
Cutaneous T-cell lymphoma (CTCL) is a group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Cutaneous T-cell lymphoma can cause rash-like skin redness, slightly raised or scaly round patches on the skin, itchy skin, discoloured patches on the skin, enlarged ly...
Find More
EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...
Find More
Pfizer’s Zirabev gets FDA nod for the treatment of five types of cancer The US FDA has approved Zirabev (bevacizumab-bvzr), a drug developed by Pfizer, for the treatment of five different types of cancer namely metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous no...
Find More
FDA grants priority review to Zejula Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro. The drug, acquired by GlaxoSmithKline along with the drugmaker Tesaro for USD 5.1 Million, has an action date of October 24, 2019. T...
Find More
Gilead jumps into a competitive Protein degradation field, signs a USD 45 M Nurix deal Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the targets are achieved the deal could reach up to USD 2.3 billion. Nurix is a drug de...
Find More
Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly co...
Find More
The medical device (MedTech) industry has small and big companies operating in various segments such.....
Find More
Pyelonephritis (Kidney infection) is an infection of the kidney, which is a consequence of urinary t.....
Find More
Acromegaly is a rare, slowly progressive disorder that is caused when the pituitary glands produce t.....
Find More
Gout is a chronic disease caused by the deposition of monosodium urate (MSU) crystals in joints. It .....
Find More
Cancer immunotherapy which is known to reactivate weakened immune cells of cancer patients, has yiel.....
Find More
BK Virus Infection , a member of the polyomavirus family, is typically associated with patients who .....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
